A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.

A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.

BACKGROUND: Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise. These adverse events (AEs) can have serious impact, and form a significant barrier to therapy adherence. Surveillance of post-marketing AEs...

Full description

Bibliographic Details
Main Authors:	Keith B Hoffman, Christina Kraus, Mo Dimbil, Beatrice A Golomb
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3425581?pdf=render

Similar Items

OA12.01. Analysis of FDA mandated dietary supplement adverse event reports (AER) 2008-2009
by: Hardy M, et al.
Published: (2012-06-01)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
by: Sakaeda Toshiyuki, et al.
Published: (2011-10-01)

Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
by: Sandra de Bie, et al.
Published: (2015-01-01)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
by: Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2011-01-01)

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
by: Toshiyuki Sakaeda, Kaori Kadoyama, Hiroaki Yabuuchi, Satoshi Niijima, Kyoko Seki, Yukinari Shiraishi, Yasushi Okuno
Published: (2011-01-01)

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
by: Takao Tamura, Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2012-01-01)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
by: Kaori Kadoyama, Ikuya Miki, Takao Tamura, JB Brown, Toshiyuki Sakaeda, Yasushi Okuno
Published: (2012-01-01)

Comparisons and Applications of Quantitative Signal Detections for Adverse Drug Reactions (ADRs): An Empirical Study Based On The Food And Drug Administration (FDA) Adverse Event Reporting System (AERS) And A Large Medical Claims Database
by: CHEN, YAN
Published: (2008)

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
by: Toshiyuki Sakaeda, et al.
Published: (2011-01-01)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
by: Dong-Hui Lao, et al.
Published: (2021-06-01)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
by: Long Meng, et al.
Published: (2021-02-01)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
by: Yusuke Kan, et al.
Published: (2021-05-01)

Adverse Events in Total Ankle Arthroplasty, Analysis of the FDA Medical and User Facility Device Experience Database
by: Karim Mahmoud MD, et al.
Published: (2019-10-01)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
by: Kavanagh KT, et al.
Published: (2019-07-01)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
by: Matthew S. Duprey, et al.
Published: (2019-08-01)

Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database.
by: Vasiliki Nikolopoulou, et al.
Published: (2019-06-01)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
by: Yinghong Zhai, et al.
Published: (2021-09-01)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021-07-01)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
by: Akiho Fukuda, et al.
Published: (2017-01-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
by: Santa Cirmi, et al.
Published: (2020-03-01)

Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database
by: Xiaojiang Tian, et al.
Published: (2021-06-01)

Bais lapidea aere clusa
by: Marc Mayer Olivé
Published: (1989-07-01)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020-09-01)

Statin-Associated Muscle Adverse Events : Update for clinicians
by: Maha A. Al-Mohaissen, et al.
Published: (2016-11-01)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
by: Elena Arrigoni, et al.
Published: (2017-01-01)

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data.
by: Homa Alemzadeh, et al.
Published: (2016-01-01)

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data
by: Alemzadeh, Homa, et al.
Published: (2017)

THPdb: Database of FDA-approved peptide and protein therapeutics.
by: Salman Sadullah Usmani, et al.
Published: (2017-01-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports
by: Judith U. Cope, et al.
Published: (2015-01-01)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
by: Paul C. Macklis, et al.
Published: (2020-06-01)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
by: Takao Tamura, Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2012-01-01)

<it>In silico </it>toxicology models and databases as FDA Critical Path Initiative toolkits
by: Valerio Luis G
Published: (2011-03-01)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
by: Kirk E Evoy, et al.
Published: (2019-04-01)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
by: Liwei Wang, et al.
Published: (2017-07-01)

OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
by: Ruwen Böhm, et al.
Published: (2016-01-01)

Pharmacogenomics of statins: understanding susceptibility to adverse effects
by: Kitzmiller JP, et al.
Published: (2016-10-01)

Adverse effects of statin therapy: real evidence
by: Marina G. Bubnova
Published: (2019-03-01)

The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins
by: Huanbiao Mo, et al.
Published: (2019-01-01)

Factors associated with statin-related adverse muscular events in adult dyslipidemic outpatients
by: Paula Ferreira Castro, et al.
Published: (2018-04-01)

Cannot write session to /tmp/vufind_sessions/sess_3enbksutumrf50n0otiglahkd8